Improving Care for Patients

Did you know that medical errors are the #3 cause of death in the U.S.? With less money than ever before and a shortage of providers attempting to serve a growing number of patients, it is no wonder that up to 1 in 2 patients may be misdiagnosed. New Medical Diagnostic AI solutions are poised to reverse this trend and dramatically improve patient care.

MaxQ AI's Video Education Series

MaxQ AI’s mission is to meaningfully reduce misdiagnosis and healthcare costs by making artificial intelligence intrinsic to the diagnostic process for time sensitive and life-threatening conditions.

Stroke and traumatic brain injury are two areas where we have initially focused. The statistics are staggering. Stroke is the second leading cause of death globally and the number one cause of disability. The cost of a missed brain bleed can be $150,000 per year patient. But, the economic cost of treating a misdiagnosed patient is nothing compared to the devastation to the families.

Our complete AccipioTM intracranial hemorrhage (ICH) platform solution is designed to enhance escalation and intervention confidence, including mobilization of the Stroke, tPA and Operating Room teams for mechanical clot removal. For example, in one industry study increased confidence in no-bleed confirmation increases the appropriate use of tPA by up to 73 percent.*

By dramatically improving a physician’s ability to make a faster, accurate and more confident diagnosis, our solutions hold significant potential to improve the quality of patient care in emergency rooms in rural and community hospitals across the globe.

You might also like:

  • Intel on AI Podcast: Revolutionizing Advanced Healthcare Imaging with MaxQ AI and Intel
  • TechTarget: AI in Radiology is having a moment – one that has staying power
  • Where is AI making the difference in radiology today?

To learn more about MaxQ AI and the premier CT OEMs, PACS software and AI Ecosystem companies deploying our solution, or to request a demo, visit us at Follow us via Twitter and LinkedIn.